Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Uniqure Ord Shs (NQ: QURE )

4.540 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 377
Open 4.540
Bid (Size) 4.500 (1)
Ask (Size) 5.000 (22)
Prev. Close 4.540
Today's Range 4.540 - 4.540
52wk Range 4.350 - 22.48
Shares Outstanding 47,838,275
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pfizer Now Rivals The World's Most Expensive Medicine After FDA Approves Gene Therapy
Pfizer won FDA approval for a new hemophilia B gene therapy, a rival to Hemgenix from CSL and Uniqure. 
Via Investor's Business Daily
Exposures Product Safety
AMD To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga

Performance

YTD
-34.49%
-34.49%
1 Month
-14.66%
-14.66%
3 Month
-21.18%
-21.18%
6 Month
-21.99%
-21.99%
1 Year
-76.53%
-76.53%

More News

Read More
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Recap: uniQure Q4 Earnings
Via Benzinga
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Bluebird Bio, Vertex Energy And Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Why Shares of uniQure Are Up Thursday
Via The Motley Fool
Why Shares of uniQure Are Dropping Tuesday
Via The Motley Fool
Topics Stocks
Exposures US Equities
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From uniQure Inc.
Via GlobeNewswire
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
From uniQure Inc.
Via GlobeNewswire
3 Micro-Cap Stocks That Could Be Moonshots
Via InvestorPlace
uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
From uniQure Inc.
Via GlobeNewswire
Gene Therapy Player UniQure To Lay Off 20% Of Workforce, Stop Parkinson's Study
Via Benzinga
uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From uniQure Inc.
Via GlobeNewswire
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
Via Investor's Business Daily
Exposures Product Safety
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy
From uniQure Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Airbnb, Blackstone Rise On News They'll Join S&P 500 Index
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Why America's Car-Mart Are Trading Lower By 12%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.